# Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

> **NCT01640340** · NA · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **DRUG:** aprepitant
- **DRUG:** palonosetron hydrochloride
- **DRUG:** ondansetron
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT01640340
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01640340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01640340, "Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01640340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*